Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions

Executive Summary

Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups

You may also be interested in...



Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More

Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.

End Of The Year Approvals And Actions, In Brief

Ferring plans prostate cancer drug launch: After securing FDA approval of degarelix for advanced prostate cancer, the Swiss pharma is planning a launch in the first quarter after finalizing the trade name with FDA. Degarelix is a gonadotropin releasing hormone receptor antagonist that suppresses testosterone, and could have an advantage over existing hormonal treatments like Abbott's Lupron Depot because it hasn't shown the initial surge in testosterone production that has been seen with some other agents, according to FDA. Testosterone plays an important role in the growth of prostate cancer, so suppressing testosterone can slow the growth and progression of prostate tumors. Degarelix was compared to leuprolide in the Phase III study supporting approval. For the U.S. launch, Ferring plans to expand its existing urology sales force from 85 reps to 115

End Of The Year Approvals And Actions, In Brief

Ferring plans prostate cancer drug launch: After securing FDA approval of degarelix for advanced prostate cancer, the Swiss pharma is planning a launch in the first quarter after finalizing the trade name with FDA. Degarelix is a gonadotropin releasing hormone receptor antagonist that suppresses testosterone, and could have an advantage over existing hormonal treatments like Abbott's Lupron Depot because it hasn't shown the initial surge in testosterone production that has been seen with some other agents, according to FDA. Testosterone plays an important role in the growth of prostate cancer, so suppressing testosterone can slow the growth and progression of prostate tumors. Degarelix was compared to leuprolide in the Phase III study supporting approval. For the U.S. launch, Ferring plans to expand its existing urology sales force from 85 reps to 115

Related Content

UsernamePublicRestriction

Register

PS048936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel